Korkut Avsar

Korkut Avsar

Auto-generated profile, based on publicly available information

Korkut Avsar

Lungenaerzte am Rundfunkplatz , Munich

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
SHSabine Hofmann-Thiel
Sabine Hofmann-Thiel
SPSara Plesnik
Sara Plesnik
MMMarina Mihalic
Marina Mihalic
MHMarion Heiß-Neumann
Marion Heiß-Neumann
KAKorkut Avsar
Korkut Avsar
HHHarald Hoffmann
Harald Hoffmann

1 August 2021 in The Lancet Infectious Diseases
Verified
Journal Article
Open access
JHJan Heyckendorf
Jan Heyckendorf
MRMaja Reimann
Maja Reimann
SMSebastian Marwitz
Sebastian Marwitz
CLChristoph Lange
Christoph Lange
KAKorkut Avsar
Korkut Avsar
TGTorsten Goldmann
Torsten Goldmann

23 January 2026 in Annals of the American Thoracic Society
Verified
Journal Article
Open access
CDCharles L Daley
Charles L Daley
JIJakko van Ingen
Jakko van Ingen
JCJames D. Chalmers
James D. Chalmers
PFPatrick A Flume
Patrick A Flume
DGDavid E Griffith
David E Griffith
KMKevin Mange
Kevin Mange
Rationale: Guidelines recommend amikacin liposome inhalation suspension (ALIS) for refractory Mycobacterium avium complex lung disease (MACLD) treatment, alongside other antibiotics. Efficacy of ALIS on microbiological endpoints and patient-reported outcomes (PROs) in the newly diagnosed MACLD population is unknown. Objectives: ARISE aimed to validate Quality of Life–Bronchiectasis Respiratory Domain (QOL-B RD) and Patient-Reported Outcomes Measurement Information System Short Form v1.0-Fatigue 7a (PROMIS F SF-7a) in patients treated for new/recurrent MACLD. We present treatment outcome results, including microbiological endpoints, PROs, and safety. Methods: Adults with noncavitary MACLD were randomized 1:1 to ALIS (590 mg) or empty liposome control (comparator), plus azithromycin (250 mg) and ethambutol (15 mg/kg) once daily for 6 months, then 1 month off treatment. Results: Of 99 patients, most had Mycobacterium intracellulare (43.4%) and/or M avium (32.3%) infections. Culture conversion with ALIS was achieved by 80.6% by month 6 (comparator, 63.9%) and 78.8% by month 7 (comparator, 47.1%; nominal P = .0010). Among patients achieving culture conversion by month 6, first negative culture defining conversion occurred at month 1 for 74.3% with ALIS (comparator, 46.7%). Mean QOL-B RD score through month 7 improved with ALIS versus plateauing with comparator after month 3; both arms showed improved PROMIS F SF-7a without between-arm difference. Positive correlations between culture conversion and improved QOL-B RD score were observed with ALIS. No ALIS-related serious adverse events or deaths were reported. Conclusions: More patients with newly diagnosed MACLD receiving 6 months of ALIS alongside a macrolide-based regimen achieved culture conversion by month 6 and month 7 numerically more rapidly versus comparator. No new safety signals were identified. Clinical trial registered with www.clinicaltrials.gov (NCT04677543).

24 June 2021 in CME
Verified
Journal Article
Open access
KAKorkut Avsar
Korkut Avsar
Obwohl die Tuberkulose mithilfe von Antibiotika gut heilbar ist und die Zahlen in Deutschland wieder stetig rückläufig sind, stirbt rechnerisch alle

25 August 2020 in medRxiv
Verified
Preprint
Open access
PDF file
JHJan Heyckendorf
Jan Heyckendorf
SMSebastian Marwitz
Sebastian Marwitz
MRMaja Reimann
Maja Reimann
KAKorkut Avsar
Korkut Avsar
ADAndrew DiNardo
Andrew DiNardo
CLChristoph Lange
Christoph Lange
Emerging multidrug-resistant tuberculosis is a major global health challenge. The World Health Organization currently recommends treatment durations of 9–18 months or more for patients with multidrug-resistant tuberculosis. We identified and validated a host-RNA signature to serve as a biomarker for individualized therapy durations for patients with multidrug-resistant tuberculosis. Adult patients with pulmonary tuberculosis were prospectively enrolled into 5 independent cohorts in Germany and Romania. Clinical and microbiological data, and whole-blood for RNA transcriptomic analysis were collected at pre-defined timepoints throughout therapy. Treatment outcomes were ascertained one year after end-of-therapy. A whole-blood RNA therapy end model was developed in a multi-step process involving a machine-learning algorithm to identify hypothetical individual end-of-treatment timepoints. Fifty patients with drug-susceptible tuberculosis and 30 patients with multidrug-resistant tuberculosis were recruited in the German identification cohorts (DS- and MDR-GIC), 28 patients with drug-susceptible tuberculosis and 32 patients with multidrug-resistant tuberculosis in the German validation cohorts (DS- and MDR-GVC), and 52 patients with multidrug-resistant tuberculosis in the Romanian validation cohort (MDR-RVC). A 22-gene RNA model that defined cure-associated end-of-therapy timepoints was derived from the DS- and MDR-GIC data. The model accurately predicted clinical outcomes for patients in the DS-GVC (AUC=0.937 [95%CI:0.899–0.976]) and suggested that cure may be achieved with shorter treatment durations for tuberculosis patients in the MDR-GIC (mean reduction 218.0 days, 34.2%, p<0.001), the MDR-GVC (mean reduction 211.0 days, 32.9%, p<0.001), and the MDR-RVC (mean reduction of 161.0 days, 23.4%, p=0.001). Biomarker-guided management may substantially shorten the duration of therapy for many patients with multidrug-resistant tuberculosis. One Sentence Summary: We identified and validated a transcriptome model based on a 22-gene signature to predict individual treatment durations for patients with multidrug-resistant tuberculosis.